Nvidia Corp. will invest $1 billion over five years to establish a new artificial intelligence laboratory in collaboration with Eli Lilly & Co. The facility, located in Silicon Valley, aims to accelerate the application of AI in the pharmaceutical industry by leveraging Lilly's lab expertise.

Eli Lilly's new oral GLP-1 drug, orforglipron, shows similar effectiveness to popular injectable medications like Ozempic for weight loss and blood sugar control in Type 2 diabetes patients. The company plans to seek FDA approval for the pill, which could revolutionize treatment options, pending its pricing strategy and safety data release.

Eli Lilly has partnered with Nvidia to develop a powerful supercomputer aimed at accelerating drug discovery. The supercomputer will leverage AI capabilities to identify new molecules and reduce the lengthy drug development process, all while running on renewable energy within Lilly's facilities.